Transcription profiling of human CML CD34+ cells during Imatinib therapy

ABSTRACT: Imatinib has become the current standard therapy for patients with chronic myelogenous leukaemia (CML). For a better understanding of the Imatinib-related molecular effects in vivo, we assessed gene expression profiles of Philadelphia Chromosome positive (Ph+) CD34+ cells from peripheral blood of 6 patients with de novo CML in chronic phase. After 7 days of treatment with Imatinib the Ph+ CD34+ cells were reassessed to look for changes in the transcriptome. The expression level of 303 genes was significantly different comparing the transcriptome of the Ph+ CD34+ cells before and after 7 days of Imatinib therapy (183 down-regulated, 120 up-regulated, lower bound ≥1.2-fold). For a substantial number of genes governing cell cycle and DNA replication, the level of expression significantly de

ORGANISM(S): Homo sapiens

SUBMITTER: Daniela Bruennert 

PROVIDER: E-GEOD-12211 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress